期刊文献+

阿托伐他汀对兔动脉粥样硬化血管内皮功能的调节 被引量:4

The adjustment of the Atorvastatin to the endothelial function of the rabbit atherosclerotic vascular
下载PDF
导出
摘要 目的探讨阿托伐他汀在兔动脉粥样硬化(Atherosclerosis,AS)一级预防中对血管内皮功能的调节。方法雄性新西兰大白兔只被随机分为动脉粥样硬化模型组(AS组)、阿托伐他汀低剂量组(LS组)和阿托伐他汀高剂量组(HS组),每组11只。所有兔子均作主动脉球囊损伤,术后第1d即开始予以下方案喂养:AS组予以高脂饲料120g/d喂养,LS组予以高脂饲料120g/d+阿托伐他汀2.5mg/d,HS组予以高脂饲料120g/d+阿托伐他汀5.0mg/d。饲养14周后全部处死。前期(球囊损伤前1d)以及后期(处死前1d)分别采静脉血检测循环中一氧化氮(Nitric oxide,NO)和内皮素(En-dothelin,ET)浓度。结果前期各组间NO、ET浓度差异无统计学意义;与前期相比,后期AS的NO明显降低及ET升高;后期时,与AS组比较,阿托伐他汀干预能使血清ET明显降低(P<0.01),NO升高(P<0.01);与低剂量组比较,高剂量组这种趋势更加明显(P<0.05)。在"球囊损伤+高脂饮食"诱导动脉粥样硬化的三组,循环中NO与ET呈负相关(r=-0.682,P<0.01)。结论血管内皮功能损害导致动脉粥样硬化的形成,阿托伐他汀干预可抑制ET分泌及促进NO分泌,从而达到调节血管内皮功能。 Objective To explore the effects atorvastatin in the regulation of vascular endothelial function for primary prevention in atherosclerosis(AS) rabbits.Methods The male New Zealand rabbits were randomly divided into atherosclerotic model group(AS group),low-dose atorvastatin group(LS group) and high-dose atorvastatin group(HS group),and each group with 11 members.All rabbits are treated as intra-aortic balloon injury.And then they began their feeding from the first day after the operation according to the following suggestion:the AS group received high-fat fodder 120g / d feeding,LS group by high-fat fodder 120g / d and atorvastatin 2.5mg / d,the HS group by high-fat fodder 120g / d and atorvastatin 5.0mg / d.14 weeks later,all of rabbits were killed.The concentration of Nitric oxide(NO) and Endothelin(ET) collected from venous blood in prophase(one day before balloon injury) and past phase(one day before death)were detected.Results In the prophase,the level of NO and ET is difference no significantly.Prophase,among the three groups show no significant difference concentrations of NO and ET.Compared with prophase,the concentration of NO is significantly reduced and ET′s is increased.at the same time,the LS group and HS group have change less than the AS group;However,the NO′s level of the AS group,LS group and the HS group in the post phase are all gradually increased(P<0.05) while the ET′s level decreased(P<0.05).further more,NO and ET was negatively correlated(r=-0.682,P<0.01).Conclusion The damage of endothelial function causes the formation of atherosclerosis;the continuing intervention of atorvastatin can inhibit ET secretion and promote NO secretion so as to adjust endothelial function.
出处 《四川医学》 CAS 2012年第11期1887-1889,共3页 Sichuan Medical Journal
关键词 动脉粥样硬化 内皮功能 阿托伐他汀 药理作用 一氧化氮 内皮素 atherosclerosis endothelial function atorvastatin pharmacological effects nitric oxide endothelin
  • 相关文献

参考文献9

  • 1Yee HS;Fong NT.Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias,1998(10).
  • 2Bot I;Jukema JW;Lankhuizen IM.Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels,2011(02).
  • 3Yonemura A;Momiyama Y;Fayad ZA.Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques:a 2-year follow-up by noninvasive MRI,2009(02).
  • 4Landmesser U;Hornig B;Drexler H.Endothelial function:a critical determinant in atherosclerosis,2004(01).
  • 5Biegelsen ES;Loscalzo J.Endothelial function and atherosclerosis[J],1999(04).
  • 6杨秀云,李杰,蔡力,陶剑虹.阿托伐他汀对过氧化物酶增殖激活受体γ表达的影响[J].实用医院临床杂志,2011,8(3):19-21. 被引量:2
  • 7Sei Nakata;Masato Tsutsui;Hiroaki Shimokawa.Statin treatment upregulates vascular neuronal nitric oxide synthase through akt/NF-kB pathway,2007(01).
  • 8Chia S;Wilson R;Ludlam CA.Endothelial dysfunction in patients with recent myocardial infarction and hyperhomocysteinaemia:effects of vitamin supplementation,2005(01).
  • 9Kaesemeyer WH;Caldwel RB;Huang J.Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions[J],1999(01).

二级参考文献9

  • 1Johnstone MT,Botnar RM,Perez AS,et al.In vivo magnetic resonance imaging of experimenttal thrombosis in a rabbit model[J].Arterioscler Thromb Vasc Biol,2001,21(9):1556-1560.
  • 2Ross R.Atherosclerosis-an inflammatory disease[J].N Engl J Med,1999,340(2):115-126.
  • 3Marx N,Sukhova G,Murphy C,et al.Macrophages in human atheroma contain PPARgamma:differentiation-depenndent perxisomal proliferator-actived receptor gamma expression and reduction of MMP-9 activity through PPARgamma acyivation in mononuclear phagocytes in vitro[J].Am J Pathol,1998,153(1):17-23.
  • 4Caroline Duval,Giulia Chinetti,Francois Trottein,et al.The role of PPARs in atherosclerosis[J].TRENDS in Molecular Medicine,2002,8(9):422-430.
  • 5Grip O,Janciauskiene S,Lindgren S.Atorvastatin activates PPAR-g and attenuates the inflammatory response in human monocytes[J].Inflammres,2002,51:58-62.
  • 6Ye Y,Nishi SP,Manickavasagam S,et al.Activation of peroxisome proliferator-activated receptor-γ(PPAR-γ)by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2[J].Prostaglandins & Other Lipid Mediators,2007,84(1-2):43-53.
  • 7Kageyama H,Hirano T,Okada K,et al.Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma[J].Biochem Biophys Res Commun,2003,305:22-27.
  • 8Malerod L,Sporstol M,Juvet LK,et al.Hepatic scavenger receptor class B,type I is stimulated by peroxisome proliferator activated receptor gamma and hepatocyte nuclear factor 4 alpha[J].Biochem Biophys Res Commun,2003,305(3):557-565.
  • 9Berger J,Moler DE.The mechanisms of action of PPARs[J].Ann Rev Med,2002,239:953-959.

共引文献1

同被引文献54

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部